80
Participants
Start Date
January 31, 2013
Primary Completion Date
September 30, 2014
Study Completion Date
September 30, 2014
Apixaban
10 mg BID for 7 days followed by 5 mg BID for 23 weeks (total 24 weeks)
Unfractionated Heparin (UFH)
Dosing adjustment based on APTT = 1.5-2.5 times the control value, and until INR ≥ 1.5 for 5 days or more
Warfarin
Dosing for 24 weeks to target INR range between 1.5-2.5
Aichi Medical University Hospital, Nagakute
Toho University Sakura Medical Center, Sakura
Kokura Memorial Hospital, Kitakyushu
Fukushima Medical University Hospital, Fukushima
Hiroshima General Hospital, Hatsukaichi
Teine Keijinkai Hospital, Sapporo
Kanazawa Medical University Hospital, Kahoku-gun
Yokohama Minami Kyousai Hospital, Yokohama
National Hospital Organization Yokohama Medical Center, Yokohama
Kumamoto University Hospital, Kumamoto
Saiseikai Kumamoto Hospital, Kumamoto
Mie University Hospital, Tsu
National Hospital Organization Okayama Medical Center, Okayama
Kinki University Hospital, Sayama
National Cerebral and Cardiovascular Center Hospital, Suita-shi
St. Luke's International Hospital, Chuo-ku
Nihon University Itabashi Hospital, Itabashi-ku
National Hospital Organization Tokyo Medical Center, Meguro-ku
Japanese Red Cross Musashino Hospital, Musashino
Tokyo Medical University Hospital, Shinjuku-ku
Lead Sponsor
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Pfizer
INDUSTRY